The immune response to Tumor Viral Infections plays a central role in determining the outcome of virus-associated cancers. Tumor cells express viral antigens, triggering immune surveillance. However, viruses often develop immune evasion strategies, allowing them to persist and contribute to cancer development. Immunotherapies have emerged as promising strategies for treating virus-associated cancers. Immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, aim to enhance the immune response against cancer cells. Adoptive T-cell therapy and therapeutic vaccines targeting viral antigens are also under investigation. The global impact of Tumor Viral Infections on cancer incidence is substantial. Cervical cancer, driven by HPV, remains a leading cause of cancer-related morbidity and mortality in many parts of the world. Liver cancer, associated with HBV and HCV, is prevalent in regions with high viral hepatitis prevalence. Global efforts to combat virus-associated cancers include vaccination programs, antiviral treatments, and cancer screening initiatives. The World Health Organization (WHO) and other international organizations advocate for comprehensive strategies to prevent, diagnose, and treat virus-related cancers, addressing both the viral infection and the associated malignancy.